Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: A Single Center, Single Arm, Phase II Clinical Study.

Next Previous
X
Search
Trial Profile

PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: A Single Center, Single Arm, Phase II Clinical Study.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary) ; Bevacizumab
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Jun 2023 Results assessing safety and efficacy of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 09 Aug 2022 Planned End Date changed from 1 Aug 2022 to 1 Oct 2024.
    • 09 Aug 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top